Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Closed
11 Jul, 20:00
NYSE NYSE
$
793. 01
+2.36
+0.3%
$
739.87B Market Cap
104.2 P/E Ratio
5.2% Div Yield
2,851,700 Volume
6.64 Eps
$ 790.65
Previous Close
Day Range
777.2 795.73
Year Range
677.09 972.53
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 25 days
Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing

Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing

The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.

Zacks | 2 weeks ago
Lilly declares third-quarter 2025 dividend

Lilly declares third-quarter 2025 dividend

INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025.

Prnewswire | 2 weeks ago
Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript

Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript

Eli Lilly and Company (NYSE:LLY ) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22, 2025 7:30 PM ET Company Participants Jeffrey Emmick - Vice President of Diabetes Product Development Kenneth L Custer - Executive VP & President of Lilly Cardiometabolic Health Michael Czapar - Director of Investor Relations Ruth Gimeno - Corporate Participant Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexandria Janet Hammond - Wolfe Research, LLC Bryan Russell Dollinger - Leerink Partners LLC, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.

Seekingalpha | 2 weeks ago
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS , June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, respectively. In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin.

Prnewswire | 2 weeks ago
Lilly expects orforglipron obesity results in third quarter

Lilly expects orforglipron obesity results in third quarter

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug in overweight and obese people without diabetes.

Reuters | 3 weeks ago
LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?

LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?

LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.

Zacks | 3 weeks ago
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 3 weeks ago
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.

Reuters | 3 weeks ago
Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug

Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug

Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug Kisunla, blocking access for patients seeking treatment under the country's state-run health service.

Reuters | 3 weeks ago
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

Zacks | 3 weeks ago
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)

Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition costs. Even though oncology, the segment in which the acquisition was made, has been lackluster in Q1 2025, it shows promise when seen over the longer term. In any case, there's a case for the company to diversify at a time when it's facing downward pressure on prices from policy, compounders, and fakes.

Seekingalpha | 3 weeks ago
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio.

Wsj | 3 weeks ago
Loading...
Load More